Biotechnology Value Fund, L.P. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (222)	7/27/1998 11:35:00 AM
From: scaram(o)uche	Read Replies (2) of 4974

BTW.... I highly recommend, if you can attend, checking out one of these Informed Investor forums. I can't believe the insight you can buy for $25. It was like a mini-H&Q with "spin". And, it's the "spin" that was most instructive. My opinion of the presentations yesterday (PDLI, SEQU and SANG were in a breakout room, and I elected to watch other presentations)...... SHMN.... very weak MBIO...... undecided SUGN..... strong, but fluff SUNP..... interesting MBIO..... Ben McGraw just didn't cover enough of the basics.... what is the selective targeting mechanism and is it good enough?? For example, he said that the "vector" that targets dividing endothelium leads to 33X uptake in new endothelial cells relative to "old". Is this good enough? What are the potential problems with tox, if any? The points are particularly relevant for the superantigen/cancer program. SUGN.... the indication was that intl. license deals are imminent.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next